Anti-glycative potential of triterpenes: A mini-review

BioMedicine (Netherlands)

Volumn 2, Issue 1, 2012, Pages 2-9

  Yin, Mei Chin ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Chronic diseases; Glycation; Triterpenes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BETULIC ACID; GLYCYRRHIZIC ACID; OLEANOLIC ACID; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TRITERPENE; URSOLIC ACID;

ALZHEIMER DISEASE; ANTIGLYCATIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; GLYCATION; HUMAN; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NEOPLASM; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 84861190837     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2011.12.001     Document Type: Review

References (102)

1. McGarvey D.J., Croteau R. Terpenoid metabolism. Plant Cell 1997, 7:1015-1026.
2. Chappell J. Biochemistry and molecular biology of the isoprenoid biosynthetic pathway in plants. Annu Rev Plant Physiol Plant Mol Biol 1995, 46:21-47.
3. Wagner K.H., Elmadfa I. Biological relevance of terpenoids. Overview focusing on mono-, di- and tetraterpenes. Ann Nutr Metab 2003, 47:95-106.
4. Xu R., Fazio G.C., Matsuda S.P.T. On the origins of triterpenoid skeletal diversity. Phytochemistry 2004, 65:261-291.
5. Abe I., Rohmer M., Prestwich G.D. Enzymatic cyclization of squalene and oxidosqualene to sterols and triterpenes. Chem Rev 1993, 93:2189-2206.
6. Connolly J.D., Hill R.A. Triterpenoids. Nat Prod Rep 2001, 18:560-578.
7. Yin M.C., Chan K.C. Non-enzymatic antioxidative and antiglycative effects of oleanolic acid and ursolic acid. J Agric Food Chem 2007, 55:7177-7181.
8. Dennehy C. Botanicals in cardiovascular health. Clin Obstet Gynecol 2001, 44:814-823.
9. Tolstikova T.G., Khvostov M.V., Bryzgalov A.O. The complexes of drugs with carbohydrate-containing plant metabolites as pharmacologically promising agents. Mini Rev Med Chem 2009, 9:1317-1328.
10. Rodríguez-Rodríguez R., Herrera M.D., Perona J.S., Ruiz-Gutiérrez V. Potential vasorelaxant effects of oleanolic acid and erythrodiol, two triterpenoids contained in 'orujo' olive oil, on rat aorta. Br J Nutr 2004, 92:635-642.
11. Channa S., Dar A., Yaqoob M., Anjum S., Sultani Z. Broncho-vasodilatory activity of fractions and pure constituents isolated from Bacopa monniera. J Ethnopharmacol 2003, 86:27-35.
12. Eleuteri E., Magno F., Gnemmi I., Carbone M., Colombo M., La Rocca G., et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci 2009, 14:2230-2237.
13. Calabrese V., Guagliano E., Sapienza M., Mancuso C., Butterfield D.A., Stella A.M. Redox regulation of cellular stress response in neurodegenerative disorders. Ital J Biochem 2006, 55:263-282.
14. Modlinger P.S., Wilcox C.S., Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004, 24:354-365.
15. Victor V.M., Apostolova N., Herance R., Hernandez-Mijares A., Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009, 16:4654-4667.
16. Willcox J.K., Ash S.L., Catignani G.L. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 2004, 44:275-295.
17. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008, 104:657-667.
18. Yao H., Yang S.R., Kode A., Rajendrasozhan S., Caito S., Adenuga D., et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem Soc Trans 2007, 35:1151-1155.
19. Morena M., Delbosc S., Dupuy A.M., Canaud B., Cristol J.P. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005, 9:37-46.
20. Sudhahar V., Kumar S.A., Varalakshmi P. Role of lupeol and lupeol linoleate on lipemic-oxidative stress in experimental hypercholesterolemia. Life Sci 2006, 78:1329-1335.
21. Sun F.Y., Chen X.P., Wang J.H., Qin H.L., Yang S.R., Du G.H. Arjunic acid, a strong free radical scavenger from Terminalia arjuna. Am J Chin Med 2008, 36:197-207.
22. Ali M.B., Yu K.W., Hahn E.J., Paek K.Y. Methyl jasmonate and salicylic acid elicitation induces ginsenosides accumulation, enzymatic and non-enzymatic antioxidant in suspension culture Panax ginseng roots in bioreactors. Plant Cell Rep 2006, 25:613-620.
23. Bayón Y., Alonso A., Hernández M., Nieto M.L., Sánchez Crespo M. Mechanisms of cell signaling in immune-mediated inflammation. Cytokines Cell Mol Ther 1998, 4:275-286.
24. Conti P., DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 2001, 22:133-137.
25. Summers C., Rankin S.M., Condliffe A.M., Singh N., Peters A.M., Chilvers E.R. Neutrophil kinetics in health and disease. Trends Immunol 2010, 31:318-324.
26. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
27. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 87:1077-1091.
28. Safayhi H., Sailer E.R. Anti-inflammatory actions of pentacyclic triterpenes. Planta Med 1997, 63:487-493.
29. Jung H.W., Chung Y.S., Kim Y.S., Park Y.K. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 2007, 39:715-721.
30. Banno N., Akihisa T., Tokuda H., Yasukawa K., Taguchi Y., Akazawa H., et al. Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica. Biol Pharm Bull 2005, 28:1995-1999.
31. Ganguly A., Das B., Roy A., Sen N., Dasgupta S.B., Mukhopadhayay S., et al. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 2007, 67:11848-11858.
32. Yan S.L., Huang C.Y., Wu S.T., Yin M.C. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol Vitro 2010, 24:842-848.
33. Harada S. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem J 2005, 392:191-199.
34. Kim J., Jang D.S., Kim H., Kim J.S. Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta. Arch Pharm Res 2009, 32:983-987.
35. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007, 62:427-433.
36. Kalousová M., Zima T., Tesar V., Dusilová-Sulková S., Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 2005, 579:37-46.
37. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997, 99:457-468.
38. Toth E., Racz A., Toth J., Kaminski P.M., Wolin M.S., Bagi Z., et al. Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH(2)/TXA(2) mediation. Am J Physiol Heart Circ Physiol 2007, 293:3096-3104.
39. Madhu S.V., Verma N.P., Goel A., Kapoor V.K. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors. J Assoc Physicians India 1992, 40:679-681.
40. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 2000, 58:3-12.
41. Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M. TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 2006, 6:351-358.
42. Takeuchi M., Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004, 63:453-455.
43. Shinohara M., Thornalley P.J., Giardino I., Beisswenger P., Thorpe S.R., Onorato J., et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998, 101:1142-1147.
44. Degenhardt T.P., Thorpe S.R., Baynes J.W. Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand) 1998, 44:1139-1145.
45. Nemet I., Varga-Defterdarović L., Turk Z. Methylglyoxal in food and living organisms. Mol Nutr Food Res 2006, 50:1105-1117.
46. Mostafa A.A., Randell E.W., Vasdev S.C., Gill V.D., Han Y., Gadag V., et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 2007, 302:35-42.
47. Takeuchi M., Sato T., Takino J., Kobayashi Y., Furuno S., Kikuchi S., et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007, 69:1358-1366.
48. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. J Gerontol A Biol Sci Med Sci 2010, 65:963-975.
49. Peppa M., Uribarri J., Vlassara H. Aging and glycoxidant stress. Hormones (Athens) 2008, 7:123-132.
50. Negre-Salvayre A., Salvayre R., Augé N., Pamplona R., Portero-Otín M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009, 11:3071-3109.
51. Tuttle K.R., Anderberg R.J., Cooney S.K., Meek R.L. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am J Nephrol 2009, 29:171-180.
52. Chandra K.P., Shiwalkar A., Kotecha J., Thakkar P., Srivastava A., Chauthaiwale V., et al. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clin Drug Investig 2009, 29:559-575.
53. Makita Z., Radoff S., Rayfield E.J., Yang Z., Skolnik E., Delaney V., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
54. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands J.L., Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008, 7:29.
55. Morcos M., Sayed A.A., Bierhaus A., Yard B., Waldherr R., Merz W., et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002, 51:3532-3544.
56. Khan Z.A., Chakrabarti S. Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007, 2007:31867.
57. Berrou J., Tostivint I., Verrecchia F., Berthier C., Boulanger E., Mauviel A., et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 2009, 23:513-520.
58. Ozdemir A.M., Hopfer U., Rosca M.V., Fan X.J., Monnier V.M., Weiss M.F. Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin. Am J Nephrol 2008, 28:14-24.
59. Jandeleit-Dahm K., Cooper M.E. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008, 14:979-986.
60. Yamagishi S., Ueda S., Matsui T., Nakamura K., Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008, 14:962-968.
61. Armstrong R.A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol 2009, 47:289-299.
62. Reddy V.P., Obrenovich M.E., Atwood C.S., Perry G., Smith M.A. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002, 4:191-209.
63. Takeda A., Wakai M., Niwa H., Dei R., Yamamoto M., Li M., et al. Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine] in Alzheimer's disease brains. Acta Neuropathol 2001, 101:27-35.
64. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001, 171:29-45.
65. Di Loreto S., Caracciolo V., Colafarina S., Sebastiani P., Gasbarri A., Amicarelli F. Methylglyoxal induces oxidative stress-dependent cell injury and up-regulation of interleukin-1beta and nerve growth factor in cultured hippocampal neuronal cells. Brain Res 2004, 1006:157-167.
66. Seidl R., Schuller E., Cairns N., Lubec G. Evidence against increased glycoxidation in patients with Alzheimer's disease. Neurosci Lett 1997, 232:49-52.
67. Bär K.J., Franke S., Wenda B., Müller S., Kientsch-Engel R., Stein G., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003, 24:333-338.
68. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001, 31:175-180.
69. Perez-Gracia E., Blanco R., Carmona M., Carro E., Ferrer I. Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathol 2009, 118:497-504.
70. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997, 23:134-147.
71. Rojas A., Figueroa H., Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010, 31:334-341.
72. Abe R., Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008, 14:940-945.
73. Wuenschell G.E., Tamae D., Cercillieux A., Yamanaka R., Yu C., Termini J. Mutagenic potential of DNA glycation: miscoding by (R)- and (S)-N2-(1-carboxyethyl)-2'-deoxyguanosine. Biochemistry 2010, 49:1814-1821.
74. Logsdon C.D., Fuentes M.K., Huang E.H., Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med 2007, 7:777-789.
75. D'Agati V., Schmidt A.M. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010, 6:352-360.
76. Uribarri J., Cai W., Sandu O., Peppa M., Goldberg T., Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005, 1043:461-466.
77. Yan S.D., Bierhaus A., Nawroth P.P., Stern D.M. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?. J Alzheimers Dis 2009, 16:833-843.
78. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000, 1498:99-111.
79. Yan S.F., Barile G.R., D'Agati V., Du Yan S., Ramasamy R., Schmidt A.M. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007, 7:146-153.
80. Shanmugam N., Kim Y.S., Lanting L., Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 2003, 278:34834-34844.
81. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007, 7:711-724.
82. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009, 13:534-539.
83. Lin L., Park S., Lakatta E.G. RAGE signaling in inflammation and arterial aging. Front Biosci 2009, 14:1403-1413.
84. Gawlowski T., Stratmann B., Ruetter R., Buenting C.E., Menart B., Weiss J., et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009, 48:475-481.
85. Nah S.S., Choi I.Y., Yoo B., Kim Y.G., Moon H.B., Lee C.K. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett 2007, 581:1928-1932.
86. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010, 391:1405-1408.
87. Liu Y., Liang C., Liu X., Liao B., Pan X., Ren Y., et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010, 208:34-42.
88. Tan A.L., Sourris K.C., Harcourt B.E., Thallas-Bonke V., Penfold S., Andrikopoulos S., et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010, 298:763-770.
89. Goldberg T., Cai W., Melpomeni P., Dardaine V., Baliga B.S., Uribarri J., et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Ass 2004, 104:1287-1291.
90. Chao P.C., Hsu C.C., Yin M.C. Analysis of glycative products in sauces and sauce-treated foods. Food Chem 2009, 113:262-266.
91. Erbersdobler H.F., Somoza V. Forty years of furosine - forty years of using Maillard reaction products as indicators of the nutritional quality of foods. Mol Nutr Food Res 2007, 51:423-430.
92. Motomura K., Fujiwara Y., Kiyota N., Tsurushima K., Takeya M., Nohara T., et al. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem 2009, 57:7666-7672.
93. Ha do T., Ngoc T.M., Lee I., Lee Y.M., Kim J.S., Jung H., et al. Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa). J Nat Prod 2009, 2:1465-1470.
94. Gugliucci A., Bastos D.H., Schulze J., Souza M.F. Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia 2009, 80:339-344.
95. Liu Y., Hartley D.P., Liu J. Protection against carbon tetrachloride hepatotoxicity by oleanolic acid is not mediated through metallothionein. Toxicol Lett 1998, 95:77-85.
96. Nguemfo E.L., Dimo T., Dongmo A.B., Azebaze A.G., Alaoui K., Asongalem A.E., et al. Anti-oxidative and anti-inflammatory activities of some isolated constituents from the stem bark of Allanblackia monticola Staner L.C (Guttiferae). Inflammopharmacology 2009, 17:37-41.
97. Yamaguchi Y., Yamada K., Yoshikawa N., Nakamura K., Haginaka J., Kunitomo M. Corosolic acid prevents oxidative stress, inflammation and hypertension in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci 2006, 9:2474-2479.
98. Wang Z.H., Hsu C.C., Huang C.N., Yin M.C. Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. Eur J Pharmacol 2010, 628:255-260.
99. Jang S.M., Kim M.J., Choi M.S., Kwon E.Y., Lee M.K. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism 2010, 59:512-519.
100. Ueno M., Nakagawa T., Wu B., Onodera M., Huang C.L., Kusaka T., et al. Transporters in the brain endothelial barrier. Curr Med Chem 2010, 17:1125-1138.
101. Pathan S.A., Iqbal Z., Zaidi S.M., Talegaonkar S., Vohra D., Jain G.K., et al. CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009, 3:71-89.
102. Chen X., Walker D.G., Schmidt A.M., Arancio O., Lue L.F., Yan S.D. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007, 7:735-742.